OC18 | ENHANCED NEUROPROTECTION BY PRIMED ADIPOSE MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES IN AN IN VITRO MODEL OF ALS
European Journal of Histochemistry · 20.11.2026 · 70 (s2)
DOI: 10.4081/ejh.2026.4812 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Histochemistry, online erschienen am 20.11.2026. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive loss of upper and lower motoneurons, leading to muscle weakness, paralysis, and ultimately respiratory failure. Despite intense research efforts, effective disease-modifying therapies remain unavailable. In recent years, extracellular vesicles derived from adipose mesenchymal stem cells (ASC-EVs) have attracted considerable attention as promising cell-free therapeutic agents owing to their neuroprotective, immunomodulatory, and anti-inflammatory properties. However, strategies aimed at further enhancing their therapeutic efficacy are still under investigation. In this study, we evaluated whether priming ASCs with pro-inflammatory stimuli could potentiate the neuroprotective activity of their released EVs in an in vitro model of ALS. The neuroprotective effects of ASC-EVs were assessed in NSC-34 motoneuron-like cells expressing human SOD1 (hSOD1) mutations associated with familial ALS (G93A, A4V, and G37R). Cell damage was induced through exposure to hydrogen peroxide (H2O2), resulting in approximately 50% cell death and providing a reproducible model of oxidative stress-related neurodegeneration. ASCs were preconditioned with either a cytokine cocktail or lipopolysaccharide (LPS), and EVs isolated from these cells were subsequently tested for their ability to promote motoneuron survival. Our findings revealed that EVs derived from primed ASCs exhibited markedly enhanced neuroprotective activity compared with EVs obtained from non-primed cells. Treatment with primed ASC-EVs significantly improved the viability of damaged SOD1-mutant motoneurons, suggesting that preconditioning enhances the biological properties of EV cargo and strengthens their capacity to counteract ALS-related pathogenic mechanisms. Overall, these results support the development of ASC-EV-based cell-free therapies for ALS and highlight cell priming as a promising strategy to maximize their therapeutic potential and translational value.
Zitieren
APA
(2026). OC18 | ENHANCED NEUROPROTECTION BY PRIMED ADIPOSE MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES IN AN IN VITRO MODEL OF ALS. European Journal of Histochemistry, 70(s2). https://doi.org/10.4081/ejh.2026.4812
Vancouver
OC18 | ENHANCED NEUROPROTECTION BY PRIMED ADIPOSE MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES IN AN IN VITRO MODEL OF ALS. European Journal of Histochemistry. 2026;70(s2). doi:10.4081/ejh.2026.4812
BibTeX
@article{euvimed2026,
title = {OC18 | ENHANCED NEUROPROTECTION BY PRIMED ADIPOSE MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES IN AN IN VITRO MODEL OF ALS},
journal = {European Journal of Histochemistry},
year = {2026},
volume = {70},
number = {s2},
doi = {10.4081/ejh.2026.4812}
}
EUVIMED